193 related articles for article (PubMed ID: 2114476)
1. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.
Richman DD; Grimes JM; Lagakos SW
J Acquir Immune Defic Syndr (1988); 1990; 3(8):743-6. PubMed ID: 2114476
[TBL] [Abstract][Full Text] [Related]
2. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Larder BA; Darby G; Richman DD
Science; 1989 Mar; 243(4899):1731-4. PubMed ID: 2467383
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of low-dose zidovudine in human immunodeficiency virus infection.
Collier AC; Bozzette S; Coombs RW; Causey DM; Schoenfeld DA; Spector SA; Pettinelli CB; Davies G; Richman DD; Leedom JM
N Engl J Med; 1990 Oct; 323(15):1015-21. PubMed ID: 1977080
[TBL] [Abstract][Full Text] [Related]
4. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.
Levacher M; Tallet S; Dazza MC; Dournon E; Rouveix B; Pocidalo JJ
Clin Exp Immunol; 1990 Aug; 81(2):177-82. PubMed ID: 1696859
[TBL] [Abstract][Full Text] [Related]
5. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
Reichman RC; Tejani N; Lambert JL; Strussenberg J; Bonnez W; Blumberg B; Epstein L; Dolin R
Antiviral Res; 1993 Apr; 20(4):267-77. PubMed ID: 8097906
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
Jackson GG; Paul DA; Falk LA; Rubenis M; Despotes JC; Mack D; Knigge M; Emeson EE
Ann Intern Med; 1988 Feb; 108(2):175-80. PubMed ID: 3124680
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
[TBL] [Abstract][Full Text] [Related]
8. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
[TBL] [Abstract][Full Text] [Related]
9. HIV antigen variability in ARC/AIDS.
Hendrix CW; Volberding PA; Chaisson RE
J Acquir Immune Defic Syndr (1988); 1991; 4(9):847-50. PubMed ID: 1910082
[TBL] [Abstract][Full Text] [Related]
10. The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.
Pedersen C; Cooper DA; Brun-Vézinet F; Doherty R; Skinhøj P; Pérol Y; Lüthy R; Leibowitch J; Habermehl KO; Varnier OE
AIDS; 1992 Aug; 6(8):821-5. PubMed ID: 1418778
[TBL] [Abstract][Full Text] [Related]
11. Effect of azidothymidine (AZT) on P24 antigen levels in patients with AIDS-related complex and AIDS.
Reddy MM; McKinley G; Englard A; Grieco MH
J Clin Lab Anal; 1989; 3(4):199-201. PubMed ID: 2503599
[TBL] [Abstract][Full Text] [Related]
12. Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine.
Williams IG; Gabriel G; Kelly G; Loveday C; Tedder RS; Weller IV
AIDS; 1990 Sep; 4(9):909-12. PubMed ID: 2123627
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.
Dis Markers; 1990; 8(3):159-61. PubMed ID: 2125536
[No Abstract] [Full Text] [Related]
14. Augmentation of cellular immune function during the early phase of zidovudine treatment of AIDS patients.
Rinaldo C; Huang XL; Piazza P; Armstrong J; Rappocciolo G; Pazin G; McMahon D; Gupta P; Fan Z; Zhang Z
J Infect Dis; 1991 Oct; 164(4):638-45. PubMed ID: 1680135
[TBL] [Abstract][Full Text] [Related]
15. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
Chaisson RE; Leuther MD; Allain JP; Nusinoff-Lehrman S; Boone GS; Feigal D; Volberding P
Arch Intern Med; 1988 Oct; 148(10):2151-3. PubMed ID: 3263098
[TBL] [Abstract][Full Text] [Related]
16. Effect of azidothymidine (AZT) on HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS.
Reddy MM; McKinley G; Englard A; Grieco MH
Int J Immunopharmacol; 1990; 12(7):737-41. PubMed ID: 2127261
[TBL] [Abstract][Full Text] [Related]
17. Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects.
Mulder JW; de Wolf F; Goudsmit J; Cload PA; Coutinho RA; Fiddian AP; Schellekens PT; van der Noordaa J; Lange JM
Antiviral Res; 1990 Mar; 13(3):127-38. PubMed ID: 1972321
[TBL] [Abstract][Full Text] [Related]
18. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.
Land S; Terloar G; McPhee D; Birch C; Doherty R; Cooper D; Gust I
J Infect Dis; 1990 Feb; 161(2):326-9. PubMed ID: 2299212
[TBL] [Abstract][Full Text] [Related]
19. Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia.
MacDonell KB; Chmiel JS; Poggensee L; Wu S; Phair JP
Am J Med; 1990 Dec; 89(6):706-12. PubMed ID: 1979205
[TBL] [Abstract][Full Text] [Related]
20. Passive immunization in ARC and AIDS.
Karpas A; Gray J; Byron N; Gilgen D; Bally V; Oates JK; Gazzard B
Biotherapy; 1990; 2(2):159-72. PubMed ID: 2144762
[No Abstract] [Full Text] [Related]
[Next] [New Search]
